Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.78 |
| ▸ | CDK8 | P49336 | 2/20 | 0.78 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.78 |
| ▸ | SGK1 | O00141 | 5/20 | 0.67 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.67 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.64 |
| ▸ | KIT | P10721 | 1/20 | 0.64 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.62 |
| ▸ | CLK1 | P49759 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.62 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8941685 | 0.89 | AXL (1.00) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL13745948 | 0.88 | AXL (0.76) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL8321586 | 0.87 | CDK8 (0.80) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL13745974 | 0.84 | CDK8 (0.66) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL1487600 | 0.84 | CAMKK2 (0.79) | AXLCDK8TNIKCAMKK2AAK1 | |
| SCHEMBL8320989 | 0.83 | AXL (0.83) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL3764839 | 0.83 | AXL (0.83) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL15833892 | 0.83 | DYRK1A (0.89) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL3771174 | 0.83 | DYRK1A (0.89) | AXLCDK8TNIKSGK1CAMKK2 | |
| SCHEMBL12763521 | 0.82 | AXL (0.76) | AXLCDK8TNIKSGK1CAMKK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | AXL 3999/4885CDK8 360/4885TNIK 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.